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ABSTRACT 
The quality indices of dihydroartemisinin–piperaquine (DP) paediatric and adult (DPP and DPA) formulations of antimalarial 
were assessed. Moisture content, viscosity, total solid for four (DPP) products along with weight uniformity, tablet hardness, 
friability, disintegration and dissolution for six (DPA) products, were determined. Assay of chemical content was performed 
using reverse phase high pressure liquid chromatographic (RP-HPLC) with Zorbax Eclipse XDB C8 column (150 x 4.6 mm, 4.6 
µm)), UV detection at 220 nm and flow rate of 0.7 mL/min. Acetonitrile: 10 mM ammonium acetate (70:30%, v/v) and tinidazole 
served as mobile phase and internal standard, respectively. Statistical analysis of data was performed using Minitab statistical 
software with one way analysis of variance comparing the parameters among the formulations and confidence interval set at 
95%. DPP products showed pH and moisture content within 3.19 to 4.65 units and 2.6 to 4.4%, respectively. Total solid and 
viscosity values were within 86.2 to 97.2% and 78.5 to 125.8 mPa.s, respectively. DPA products had comparable and satisfactory 
weight uniformity, hardness, friability and disintegration tests results except DPA5 and DPA6 which failed the weight uniformity 
tests featuring tablets with deviation from the mean above 5%. All DPP products passed chemical content test with values within 
92.65 to 101.22% while DPA2, DPA4 and DPA5 failed. All DPA products showed poor dissolution characteristics with C40 
values below 60% and T70 values above 70 min. All DP products showed varying physicochemical properties that may give 
differing drug performance in vivo. 
Key words: Dihydroartemisinin-piperaquine, antimalarial, physicochemical properties, Chemical content, biopharmaceutical 
indices. 
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INTRODUCTION  
Malaria ranks high among the causes of morbidity and 
mortality worldwide
1
. It is a health problem recording 
over 300 million diagnosis yearly, according to World 
Health Organization reports
2
. The World Health 
Organization advocates effective treatment of malaria 
infection which is premised on the use of efficacious 
antimalarial agents taken according to an optimized 
regimen
3
.  
Resistance to antimalarial agents has been reported 
severally. Developments of newer agents and 
recommendations on combination therapy involving 
the artemisinin derivatives have been particularly 
effective because they act rapidly and are well 
tolerated
4
. However, artemisinin- based combination 
therapy (ACT) drugs have also been birthed with 
parasite resistance
5, 6
. The battle against parasitic 
resistance to antimalarial agents is ongoing. 
Among the fixed-dose combination (FDC) 
artemisinin-based combination therapy (ACT) in wide 
use, dihydroartemisinin-piperaquine (DP) has been 
reported to give  rapid initial reduction in parasite 
biomass while the sustained effect of the more slowly 
eliminated partner drug prevents the subsequent 
recrudescence of the infection
7
. DP has been 
recommended by WHO since 2010 for the treatment 
of uncomplicated falciparum malaria
5
. The drug offers 
a promising alternative to other currently available 
ACTS because of its high efficacy, excellent safety 
profile, good rating of compliance (once daily dosing 
scheme) and its prolonged post–treatment 
prophylaxis
8, 9
. 
The physiochemical properties of these co-formulated 
drugs describe the ultimate benefit from the product. 
Dihydroartemisinin (DHA) is a molecule with intrinsic 
chemical instability and has been reported unsuitable 
for use in pharmaceutical formulations
10
. Data have 
shown that currently marketed DHA preparations 
failed to meet the internationally accepted stability 
requirements
10
. At a time when concerted efforts 
aimed to ban counterfeit and substandard medicine 
from the malaria market it becomes worrisome that 
World Health Organization and Public Private 
Partnership Ventures (PPPV) can support the 
production and marketing of antimalarial drugs (i.e., 
dihydroartemisinin) with such spurious 
physiochemical properties
10
. Piperaquine the co-
formulated partner is also was used earlier  
This present study aimed at assessing the 
physiochemical parameters bothering on the quality 
characteristics of adult and paediatric formulations of 
DP products in the Nigerian market. 
MATERIALS AND METHODS 
Chemicals 
Piperaquine reference powder was kindly donated by 
Central Research Laboratory of University of Lagos. 
Methanol, ammonium acetate and acetic acid were of 
high pressure liquid chromatographic (HPLC) grade. 
Deionized water was used throughout the study. 
Generic DP paediatric and adult products were 
purchased from registered pharmacy in Uyo, Southern 
Region, Nigeria. Details of drug products are listed in 
Table 1 and Table 2. 
Stock solution preparation 
Reference standard piperaquine (10 mg) was 
accurately weighed and transferred to 10 mL 
volumetric flask. A volume of 6 mL of the mobile 
phase consisting of acetonitrile: 10 mM ammonium 
acetate with 2 mM 1-octanesulfonic acid sodium 
(70:30%, v/v) were added. The mixture was shaken 
and sonicated for 10 min to dissolve and thereafter 
filtered through a 0.45 µm nylon membrane fitter. The 
filtrate was further diluted to mark.  
 
Table 1: Details of generic DP paediatric products 
 
 
 
Product 
code 
Details of products 
 
Trade 
name 
Source and 
batch number 
Mf/ Ex 
date 
NAFDAC 
Reg. 
number 
Colour 
of 
powder 
Odour / 
Colour on 
reconstitution 
Taste Texture 
DPP1      P-
Alaxin 
India 
PDS010 
11/2014 
10/2016 
Yes Cream Metallic 
/Orange 
Bitter Fine 
DPP2 Kinotem 
Powder 
China 
150715 
07/2015 
07/2018 
Yes Pink Strawberry 
/cream 
Sweet Coarse 
DPP3 Falcidin Vietnam 
13001CX 
09/2013 
09/2016 
Yes Orange Brick/Brown Sweet Coarse 
DPP4 Solartep China 09/2016 Yes Orange Orange Sweet Fine 
*Mf/Ex date represents manufacturing/Expiry date; NAFDAC Reg. represents National Agency for Food and Drug 
Administration and Control registration number. 
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Table 2: Details of generic DP adult product 
Product code Details of products 
Trade name Source Mf/Ex. Date NAFDAC Registration 
DPA1 Axcin DP China 09/14 - 09/17 Yes 
DPA2 Terocan India 01/15 - 12/17 Yes 
DPA3 Kenmekaxin P India 12/14 - 12/17 Yes 
DPA4 Krosh China 10/14 - 10/17 Yes 
DPA5 Fanmet China 06/14 - 06/17 Yes 
DPA6 D-Artep China 09/14 - 09/17 Yes 
*Mf/Ex date represents manufacturing/Expiry date 
 
Preparation of internal standard solution (ISS)  
Pure reference powder of tinidazole (20 mg) was 
accurately weighed and transferred into a 0.5 L beaker. 
This was shaken and dissolved in 100 mL of the 
mobile phase. The solution was transferred to a 1 L 
volumetric flask and made up to mark to produce a 0.2 
%, w/v solution. 
Physicochemical properties  
Viscosity  
The powder products of DP were reconstituted with 30 
mL of distilled water, shaken well to disperse and 
made up 60 mL mark. The viscosity of the 
reconstituted products was measured using a 
viscometer (Mettler Toledo, Germany). A volume of 
20 mL of the suspension was placed between the cone 
and the basal plate at temperature of 32
o
C with 
rotation of 5 rpm for 5 mm. 
Moisture content    
Moisture content of the DPP formulations were 
determined using 1 g of powder in a moisture analyzer 
(PCE-MB 210C, UK) and heating up to a temperature 
of 105
o
C. The moisture content determination was 
performed in triplicate.  
Determination of pH 
The probe of pH meter (Mettler Toledo, Germany) 
was dipped into a 100 mL beaker containing 50 mL of 
the reconstituted product at temperature of 25
0
 C and 
the pH determined. This was performed in triplicate. 
Total solid  
A volume of 20 mL of reconstituted powder was 
sampled using a pipette from the same depth and (n=3) 
dispensed into porcelain dishes of known weight 
(W1). The dishes were placed on water bath to allow 
the content evaporate to dryness. These were afterward 
placed in an oven Gallenkamp No. 335 (England). The 
dishes were removed and allowed to cool 
intermittently while weighing, till a constant weight 
was observed, (W2). The difference in weight (W1-
W2) was obtained and the total solid percent 
determined. This was performed in triplicate. 
Weight uniformity test 
Twenty tablets from each of the 6 brands of DP 
generic were randomly sampled and weighed using a 
digital weighing balance (Adventure Ohaus, 
China).The mean weight and percent deviation of each 
tablet weight from the mean were determined. 
Friability test 
Ten tablets from each of the six brands of DP tablets 
were randomly sampled. The total weights of tablets 
for each brand were recorded (W1).The tablets for 
each brand was transferred in turns into tablet 
Friabilator (Roche, UK). The final weights for each 
brand were determined after 100 cycles of tumblings 
of the tablets, (W2). The difference in weight (W1-
W2) was determined and the percentage weight loss 
calculated from Equation 1. 
             
     
  
     ….(1) 
Disintegration Test 
A tablet each was placed in the basket disc of digital 
tablet disintegration tester, (TF – 2D, UK). The tester 
was operated at 37
o
C while the time for complete 
disintegration of tablet (with no palpable remains of 
the tablet on the basket). 
Hardness Test  
Ten tablets from each brand were randomly selected 
and each tablet placed between the jaws of hardness 
tester (Mosanto, England). The force (KgF) required 
to break the tablets were determined.  
Dissolution Test  
The dissolution profiles for the DP brands were 
determined using 500 mL of 0.1 N hydrochloric acid 
as dissolution media in a dissolution apparatus model 
RCZ-6C3, (China,). The system was maintained at 
37
o
C and stirring speed of 100 rpm. A volume of 5 mL 
was sampled at 0, 5, 15, 20, 30, 60 and 15 min while 
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same amount of fresh medium replaced after each 
sampling. 
Chemical content determination 
Preparation of graded concentrations 
Graded concentrations of piperaquine were prepared 
from the stock solution using the dilution formula. The 
ISS was spiked into the graded concentrations at a 
final concentration of 20 µg/mL and ready for 
injection. The graded concentrations were used to 
prepare the calibration curves. 
Preparation of samples from products 
Three randomly selected samples from the DPP 
products were obtained. An equivalent weight of 50 
mg piperaquine was accurately taken from each of the 
containers. Similarly, a total of 10 tablets from each of 
the DP adult products were randomly selected and 
weighed together. The average weight was calculated. 
The tablets were crushed and triturated together. 
Equivalent weights of 50 mg piperaquine were 
calculated and accurately weighed for each of the 
products. This was dissolved in 100 mL of mobile 
phase by shaking and sonication. The solutions were 
filtered using 0.45 µm acrodysc syringe filter. The 
resulting solutions were further diluted to produce a 30 
µg/mL working concentration. The final concentration 
was spiked with ISS to produce 20 µg/mL.  The 
amount of piperaquine was determined using HPLC 
system  
Statistical Analysis 
Data obtained were analyzed with Minitab statistical 
package (Minitab Inc., USA), using one way analysis 
of variance (ANOVA) and significant difference 
between values among products indicated at p < 0.05. 
RESULT AND DISCUSSION 
This study assesses the physicochemical properties of 
DP products after they have been released to the 
market (i.e., within their shelf life). Marketing of 
adulterated and substandard antimalarial drugs have 
been reported in the study area
11
. Speculations of drug 
product instability are also associated with the 
dihydroartemisinin content of this particular co-
formulated product. 
The physicochemical properties that relate to quality 
have been investigated for the paediatric products (i.e., 
pH, moisture content, total solid and viscosity. The 
adult formulation has been evaluated and quality 
assessment based on uniformity of weight 
determination, tablet hardness test, friability and 
disintegration test. Several reports have presented the 
unreliability of dihydroartemisinin level quantization 
in DP formulations 
12
 while some other workers have 
also presented some validated methods for 
determination of dihydroartemisinin alone
13
 and 
simultaneous determination of both drugs in DP
14, 15
. 
In this study, the piperaquine component has been 
followed up for the quality assessment of the DP 
products.  
Table 3 presents the results of the physicochemical 
properties analyses for the paediatric products of DP. 
The outcome of pH for the products gave a 
significantly higher value for DPP1 compared with the 
other investigated products, p < 0.05. The levels of pH 
in products affect the chemical stability of the drug or 
drug product. In cases where pH varied significantly, it 
is expected that the chemical content be affected 
accordingly. In the same vein, the amount of moisture 
in the powdered product plays a significant role in the 
chemical stability, crystal structure, powder flow and 
in the dissolution while reconstitution for use. 
Products with high moisture content have been 
observed with aggregation of tablets and caking. 
Among the products, DPP3 had a high moisture 
content percent that may cause decomposition of 
susceptible active ingredient. Products with high 
moisture content have characteristically poor 
dissolution profile. All the products have higher than 
expected moisture content percent that gives an 
indication that the actives or excipients have 
absorptive tendencies. Manufacturers of paediatric DP 
products may therefore need to present formulations 
with lower moisture content powder with better free 
flowing character. 
 
Table 3: Physicochemical properties of DP powder for paediatric suspension 
Product code Physicochemical parameters   (n=3) 
 pH Moisture content (%) Total solid (%) Viscosity (mPa.s) 
DPP1 4.65.±.0.02 3.9 ± 0.12 91.3.±.0.7 78.5 ± 6.9 
DPP2 3.52 ±.0.01 2.6 ± 0.06 97.2.±.1.4 125.8.±.3.7 
DPP3 3.56 ± 0.05 4.4 ± 0.02 86.2 ± 3.7 85.8 ± 3.5 
DPP4 3.19 ± 0.03 4.1 ± 0.04 94.8 ± 5.8 98.3 ± 1.4 
*mPas.s represents millipascal-second 
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Product DPP2 presents with significantly higher 
viscosity compared to the other products, p < 0.05. 
The viscosity observed for DPP2 may be a function of 
the excipients employed in the formulation. The 
choice of excipients to improve the thickness of 
powders for reconstitution however should be 
carefully selected to allow the timely release of the 
actives from the formulation
18
. Products with high 
viscosity are known to have low release rates of the 
active ingredients from the tablet matrix. There was no 
significant difference in the total solid percent of the 
sampled DPP products, p > 0.05.  
The maximum deviations from the mean of tablet 
weights for the selected DP products were within the 
pharmacopoeia range of not more than 5% except 
product DPA5 and DPA6 (Table 4). None of the 
tablets in these products had twice as much deviation. 
Only one of the tablets in the two groups had this 
deviation. Hardness test for all the products lay within 
3.24 to 8.60 kgF. These values are acceptable range 
for conventional immediate release tablets (Table 4). 
Values below 3.0 are common with chewable tablets
16, 
17
. Friability values for the products lay within 0.111 
to 0.343 therefore considered to have satisfactory 
indices. Evaluation of the disintegration time for the 
tablets also gave satisfactory values (1.45 to 17.82 
min). The general comment on these paediatric 
products therefore is that the manufacturing processes 
by the various sources have strived to achieve quality 
products by adhering to standard operating procedures.
 
Table 4:  Physical parameters for DPA products 
Product code Some physical parameters of DP adult products 
Maximum deviation from mean 
weight (%) 
Hardness test 
(kgF) 
Friability Disintegration time 
(min) 
DPA1 1.708 5.99 0.111 11.60 
DPA2 2.877 6.82 0.116 1.45 
DPA3 3.600 5.34 0.140 5.82 
DPA4 2.700 8.60 0.125 10.44 
DPA5 5.061 3.24 0.343 17.82 
DPA6 6.694 6.49 0.141 1.78 
 
The coefficient of regression (R
2
) for the calibration 
plot for the determination of piperaquine in the drug 
products was 0.997. Piperaquine chemical contents for 
the various DP products varied significantly, p<0.05.  
Table 5 presents the mean piperaquine contents and 
their respective standard deviation values. It was 
observed that the values for the paediatric products lay 
within the International Pharmacopoeia specification 
of between 90% and 110% while some of the adult 
products (DPA2, DPA4 and DPA5) fell out of the 
range with values above 110%
19
.  
 
Table 5: Chemical content of paediatric and adult products of DP 
Product code Chemical content Comment 
DPP1 98.23 ± 5.65 S 
DPP2 92.65 ± 3.14 S 
DPP3 101.22 ± 4.65 S 
DPP4 96.48 ± 8.62 S 
DPA1 107.53 ± 2.85 S 
DPA2 125.0 ± 7.73 NS 
DPA3 93.50 ± 7.40 S 
DPA4 131.47 ± 8.84 NS 
DPA5 114.33 ± 8.20 NS 
DPA6 104.33 ± 9.64 S 
*S and NS represent satisfactory and not satisfactory values with respect to International Pharmacopoeia specifications for 
actives in drug products. 
 
The selected products had variable dissolution profile 
in 0.1 N hydrochloric acid. Figure 1 expresses the 
dissolution chart of the six DPA products. The 
dissolution parameters are laid out in Table 6.  
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Figure 1: Dissolution profile for DP tablets following piperaquine release DPA1♦, DPA2▄, DPA3▲, DPA4×, 
DPA5* and DPA6•) 
 
Dissolution tests specification according to USP 2014 
states that each unit should have not less than Q+5% 
of the active ingredient dissolved in 60 min for the six 
units or tablets. If the requirement is not met, another 
six units should be tested and the mean percent 
dissolution for the twelve units should be less than Q% 
and none of the units should be less than Q-15 %. It 
was necessary to compare the percentage dissolved 
statistically so as to compare the various DPA 
products in circulation for their pharmaceutical 
equivalence
200
. 
The area under the curve (AUC) for each product was 
calculated as  
     
                  
 
   
   …(2) 
“ti’ is the ‘ith’ time point and ‘yi’ the percentage of 
dissolved product at time ‘ti’. The AUC of the 
products relates to their rate and extent of drug release 
and in many drugs may correlate with the 
bioavailability. The AUC for the adult products 
showed statistically significant difference among the 
products p>0.05. None of the DPA products had 
satisfactory dissolution profile with respect to 
piperaquine release. The amount released at 40 min 
(C40) for the products vary widely and in the range 
(30.0 to 46.7%). DPA1, DPA2, DPA4 and DPA5 did 
not achieve 70% dissolution within the experimental 
time of 90 min. 
Table 6 presents the dissolution profile of the generic 
DPA in the study. Dissolution efficiency was 
calculated as 
   
    
  
  
            
    ….(3)
 
Table 6: Dissolution parameters for DPA products 
Product code Dissolution parameters 
C40 
(%) 
T70 
Min 
AUC 
%.min 
DE  
DPA1 46.7 ± 2.54 ** 3684.0 1.0  
DPA2 40.0 ± 1.79 **        3329.35 0.90  
DPA3 33.0 ± 0.45 70.0 ± 2.55 3042.88 0.83  
DPA4 56.0 ± 5.12 ** 4560.60 1.24  
DPA5 40.0 ± 2.86 ** 3273.25 0.89  
DPA6 30.0 ± 3.65 85.0 ± 4.90 3771.50        1.02 
*C40, T70, AUC, DE, represent the amount of drug released at 40 min, time to achieve 70% dissolution, area under the 
concentration time curve, dissolution efficiency for the drug products.   
**Values outside of dissolution experimental time. 
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CONCLUSION 
The sampled DP products exhibited varying 
physicochemical properties that may present different 
drug performance. The quality characteristics of the 
products also varied significantly among the products. 
There is the need for a standard operating procedure 
for the manufacture of DP paediatric and adult 
products for bioequivalence considerations. 
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